

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2021 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorials**677** Greetings from the editor

J S Smolen

OPEN ACCESS

679 Rheumatology and COVID-19 at 1 year: facing the unknowns

L Calabrese, K L Winthrop

Heroes and pillars of rheumatology**682** Joachim Robert Kalden: one of the founders of autoimmunity research and immunotherapy

G-R R Burmester, B Manger, G Schett, H Schulze-Koops

685 Charles L Christian: model physician scientist and mentor

M K Crow

Review**689** Functional genomics of autoimmune diseases

A Suzuki, M M Guerrini, K Yamamoto



EDITOR'S CHOICE

Recommendations**698** EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19

A Alunno, A Najm, P M Machado, H Bertheussen, G R Burmester, F Carubbi, G De Marco, R Giacomelli, O Hermine, J D Isaacs, I Koné-Paut, C Magro-Checa, I McInnes, P L Meroni, L Quartuccio, A V Ramanan, M Ramos-Casals, J Rodríguez Carrio, H Schulze-Koops, T A Stamm, S W Tas, B Terrier, D G McGonagle, X Mariette

707 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice

V Ritschl, T A Stamm, D Aletaha, J W J Bijlsma, P Böhm, R G Dragoi, E Dures, F Estévez-López, L Gossec, A Iagnocco, A Marques, E Moholt, M Nudel, B J F van den Bemt, K Viktil, M Voshaar, A de Thurah, L Carmona

714 'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models

S Hayer, M J Vervoordeldonk, M C Denis, M Armaka, M Hoffmann, J Bäcklund, K S Nandakumar, B Niederreiter, C Geka, A Fischer, N Woodworth, S Blüml, G Kollias, R Holmdahl, F Apparailly, M I Koenders

Rheumatoid arthritis**727** Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

R Westhovens, W F C Rigby, D van der Heijde, D W T Ching, W Stohl, J Kay, A Chopra, B Bartok, F Matzkeis, Z Yin, Y Guo, C Tasset, J S Sundry, A Jahreis, N Mozaaffarian, O D Messina, R BM Landewé, T Atsumi, G R Burmester

739 Novel autoantibodies identified in ACPA-negative rheumatoid arthritis

K Li, W Mo, L Wu, X Wu, C Luo, X Xiao, X Jia, H Yang, Y Fei, H Chen, F Zhang, Y Li, L Zhao, X Zhang

748 TNF is a homeostatic regulator of distinct epigenetically primed human osteoclast precursors

C Ansalone, J Cole, S Chilaka, F Sunzini, S Sood, J Robertson, S Siebert, I B McInnes, C S Goodyear

Systemic lupus erythematosus**758** Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus

C Adamichou, I Genitsaridi, D Nikolopoulos, M Nikoloudaki, A Repa, A Bortoluzzi, A Fanouriakis, P Sidiropoulos, D T Boumpas, G K Bersias

767 New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE

L P Whittall Garcia, D D Gladman, M Urowitz, Z Touma, J Su, S R Johnson

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008
J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

When you have finished with this please recycle it

- 775** European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
M Aringer, R Brinks, T Dörner, D Daikh, M Mosca, R Ramsey-Goldman, J S Smolen, D Wofsy, D T Boumpas, D L Kamen, D Jayne, R Cervera, N Costedoat-Chalumeau, B Diamond, D D Gladman, B Hahn, F Hiepe, S Jacobsen, D Khanna, K Lerström, E Massarotti, J McCune, G Ruiz-Irastorza, J Sanchez-Guerrero, M Schneider, M Urowitz, G Bertsias, B F Hoyer, N Leuchten, G Schmajuk, C Tani, S K Tedeschi, Z Touma, B Anic, F Assan, T M Chan, A E Clarke, M K Crow, L Cziráková, A Doria, W Graninger, B Halda-Kiss, S Hasni, P M Izmirly, M Jung, G Kumánovics, X Mariette, I Padjen, J M Pego-Reigosa, J Romero-Diaz, Í Rúa-Figueroa, R Seror, G H Stummvoll, Y Tanaka, M G Tektonidou, C Vasconcelos, E M Vital, D J Wallace, S Yavuz, P L Meroni, M J Fritzler, R Naden, K Costenbader, S R Johnson

- 782** Arg206Cys substitution in DNASE1L3 causes a defect in DNASE1L3 protein secretion that confers risk of systemic lupus erythematosus
L N Coke, H Wen, M Comeau, M H Ghanem, A Shih, C N Metz, W Li, C D Langefeld, P K Gregersen, K R Simpfendorfer

Autoinflammatory disorders

- 788** Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features
D M Schwartz, M M Kitakule, B LP Dizon, C Gutierrez-Huerta, S A Blackstone, A M Burma, A Son, N Deutch, S Rosenzweig, H Komarow, D L Stone, A Jones, M Nehrebecky, P Hoffmann, T Romeo, A A de Jesus, S Alehashemi, M Garg, S Torreggiani, G A Montealegre Sanchez, K Honer, G Souto Adeva, K S Barron, I Aksentijevich, A K Ombrello, R Goldbach-Mansky, D L Kastner, J D Milner, P Frischmeyer-Guerreno

Treatment

- 796** Non-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitation
S Cedergqvist, T Flinckbilä, M Sormaala, J Ylinen, H Kautiainen, T Irmola, H Lehtokangas, J Liukekonen, K Pamilo, T Ridanpää, K Sirmö, J Leppilähti, I Kiviranta, J Paloneva

Epidemiology

- 803** Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider
A Alunno, A Najm, X Mariette, G De Marco, J Emmel, L Mason, D G McGonagle, P M Machado

Letters

- 816** Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey
C Campochiaro, G Trignani, A Tomelleri, S Cascinu, L Dagna, COVID-19 Vaccine Study Group
- 817** SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease
K M D'Silva, N Serling-Boyd, T Y-T Hsu, J A Sparks, Z S Wallace
- 819** PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic
J Spierings, V Ong, C P Denton
- 820** Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China
Y You, C Shi, Z Zhou, F Wang, Y Sun, J Teng, H Liu, X Cheng, Y Su, H Shi, C Yang, J Ye

Electronic pages

- e85** Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience
R A Pineda-Sic, D A Galarza-Delgado, G Serna-Peña, S A Castillo-Torres, D E Flores-Alvarado, J A Esquivel-Valerio, I D J Hernández-Galarza
- e86** Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic *et al*
H Schulze-Koops, K Krueger, C Specker, On behalf of the Kommission Pharmakotherapie of the German Society of Rheumatology
- e87** Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis
A H Györfi, M Köpp, M May, M Vetter, M Uder, A E Kremer, G Schett, T Harter, J H W Distler

- e88** Response to: 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis' by Györfi *et al*
M Gianfrancesco, K L Hyrich, J Yazdany, P M Machado, P C Robinson
- e89** Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic
A Lecler, D Villeneuve, C Vignal, T Sené
- e90** Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler *et al*
S Monti, C Montecucco
- e91** Comparative analysis of synovial inflammation after SARS-CoV-2 infection
S Alivernini, A Cingolani, M Gessi, A Paglionico, G Pasciuto, B Tolusso, M Fantoni, E Gremese
- e92** Response to: 'Comparative analysis of synovial inflammation after SARS-CoV-2 infection' by Alivernini *et al*
M-C López-González, V Jovani, E Merino, P Vela, M Andrés
- e93** COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre
N Cleaton, S Raizada, N Barkham, S Venkatachalam, T Sheeran, T Adizie, H Sapkota, B Singh, J Bateman
- e94** Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments
Z Gendebien, C von Frenckell, C Ribbens, B André, M Thys, M Gangolf, L Seidel, M G Malaise, O Malaise
- e95** COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study
M Kasap Cuceoglu, E D Batu, Y Bilginer, S Özen
- e96** Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu *et al*
C Salvarani, G Bajocchi, P Mancuso, E Galli, F Muratore, P Giorgi Rossi
- e97** Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak
H So, C-C Szeto, L-S Tam
- e98** Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So *et al*
H Schulze-Koops, C Specker, K Krueger
- e99** Mild COVID-19 in ANCA-associated vasculitis treated with rituximab
S Suárez-Díaz, C Morán-Castaño, R Coto-Hernández, L Mozo-Avellaneda, C Suárez-Cuervo, L Caminal-Montero
- e100** COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic
R O Akintayo, A Akepbio, A Kalla, D Dey, A Migowa, H Olaosebikan, R Bahiri, Y El Miedany, D Hadej, W Hamdi, O Oyoo, S Slimani, A Yerima, Y Taha, A Adehajo, O Adelowo, M Tikely, I Ghozlani, K B Abdelghani, N A Fouad, D Mosad, D El Mikkawy, M H Abu-Zaid, R A Abdel-Magied
- e101** Case of acute arthritis following SARS-CoV-2 infection
N Yokogawa, N Minematsu, H Katano, T Suzuki
- e102** Impact of the COVID-19 lockdown on the management and control of patients with GCA
R Pralraud, H Greigert, M Samson, M Zeller, M Boulin, P Bielefeld, A Ramon, Y Cottin, B Bonnotte